WTTW News10h
New Rules for Asthma Treatment Pit Insurer Against Some Patients, Providers in Illinois
People with severe asthma insured by BlueCross BlueShield of Illinois may soon face a new hurdle in accessing a treatment ...
Healio14h
Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent
Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for prostate cancer ...
STAT14h
Alnylam drug wins FDA approval for progressive heart disease
Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...
Zacks Investment Research on MSN15h
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia
Esperion Therapeutics ESPR announced that it has come to an alignment with the FDA for initiating two phase III studies. The ...
Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory
Soleno Therapeutics is nearing FDA approval for its lead drug, DCCR, targeting Prader-Willi Syndrome, a rare genetic ...
Telix Pharmaceuticals' New Drug Application for Prostate Imaging Drug Gets FDA Approval
Telix Pharmaceuticals' said its new drug application in the U.S. for an imaging agent received regulatory approval. The Melbrourne, Australia-based biopharmaceutical company said Friday that the Food ...
Novartis1d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...